Table 5 Demographic and clinical characteristics, and plasma concentrations and metabolic ratios in study groups
|  | Responders (n = 39) | Non-responders (n = 29) | Statistics | p |
|---|---|---|---|---|
Age | 41.54 (11.60) | 45.38 (10.86) | t = 1.387 | 0.170 |
Sex, M/F | 17/22 | 15/14 | χ2 = 0.442 | 0.625 |
Illness duration, year | 12.59 (8.53) | 16.21 (8.29) | t = 1.752 | 0.084 |
PANSS, baseline | 89.13 (7.65) | 87.69 (8.41) | t=-0.735 | 0.465 |
BPRS, baseline | 46.08 (5.23) | 46.45 (5.44) | t = 0.285 | 0.777 |
Dose | 5.26 (0.99) | 3.93 (0.92) | t=-5.609 | < 0.001 |
RIP, PC | 4.5 (2.4–14.20) | 7.90 (2.65–15.90) | t=-0.187 | 0.853 |
9-OH-RIP, PC | 41.00 (30.80–50.20) | 27.80 (21.45–32.50) | t=-2.457 | 0.017 |
Active moiety | 51.90 (35.70–63.40) | 36.20 (30.35–43.85) | t=-2.032 | 0.046 |
RIP/9-OH-RIP | 0.14 (0.07–0.39) | 0.27 (0.12–0.49) | t = 1.016 | 0.313 |
RIP/D | 0.93 (0.48-3.00) | 1.98 (0.60–4.13) | t = 1.128 | 0.263 |
9-OH-RIP/D | 8.00 (5.75–10.03) | 6.88 (5.54–9.70) | t = 0.498 | 0.620 |
C/D | 9.30 (6.68–9.30) | 9.30 (7.03–15.87) | Z=-0.155 | 0.887 |